RE:What will it takeMikee3003 wrote: Getting the stock price higher.
a. close the next pp - the last raises did nothing so why would the latest?
b. receiving BTD - many feel that BTD will give the stock price a rerating, I have my doubts as this does not resolve the financial challenges we now face......the relentless shylocks will be watching!
c. further excellent clinical results - no, did nothing before so expect nothing again!
d. change in leadership and bod - imo this would be one of the keys!
e. partnership, distribution deal, licensing deal - imo this might be the only way to get a stock price rerate!
d. hostile takeover - yes please!
If they get BTD I do expect a re-rate as it significantly alters the market perception of commercial advancement. I'd expect a market cap re-rate toward $200M at minimum (albeit the huge warrant overhang and expiry timeline could be a sp drag).
We must keep in mind there are a lot of successful ph2 companies that achieve a market cap of 10 - 15% of peak potential sales, at minimum, while still having to face an arduous ph3 trial. For Theralase this trial is the equivalent of their ph3, it's well advanced and growing more de-risked with each update.
Each de-risking milestone toward commercialization should carry with it a stair step re-rating. I'd also argue that receiving BTD would open a lot of doors and initiate a lot of interested party discussions toward a licensing or j/v deal.
A BoD shakeup and the hiring of a strong advisory team would be money well spent when they have it but we're most certainly stuck with this ceo. Alll imo.